About Us

OnConquer Medical is developing a first-in-class intravascular therapeutic platform designed to reduce metastatic risk by physically intercepting circulating tumor cells (CTCs) during cancer surgery and the immediate postoperative period—an interval when conventional chemotherapy and biologic therapies are typically not administered.

 

Since its establishment, the company has completed more than 60 in-vitro flow-based studies demonstrating high-efficiency CTC capture under physiologic conditions and has progressed to in-vivo studies focused on reducing metastatic burden.

 

OnConquer Medical has also been awarded three competitive, non-dilutive grants from the Israel Innovation Authority and has filed a patent application protecting its core CTCapture® technology for metastasis prevention.